Respiratory distress syndrome remains a significant cause of morbidity among preterm infants, primarily due to surfactant deficiency that compromises lung function. Traditional management involves surfactant delivery via endotracheal intubation and mechanical ventilation, which, while life-saving, carries risks of barotrauma, volutrauma, and subsequent chronic lung disease. The LISA protocol, emphasizing minimally intrusive surfactant delivery, aims to mitigate these complications by administering surfactant while the infant maintains spontaneous breathing on non-invasive ventilation.

The multi-institutional study led by Ariyapadi and colleagues meticulously analyzed infants between 30 and 34 weeks gestational age—a critical developmental period where pulmonary immaturity pronounces RDS vulnerability. The research team implemented a defined respiratory care pathway incorporating LISA, rigorously comparing respiratory outcomes, intervention rates, and neonatal morbidity indicators against conventional treatment modalities.

Key findings underscored significant reductions in the duration and necessity of mechanical ventilation among infants treated with the LISA protocol. This less invasive method fostered enhanced lung recruitment and surfactant distribution by preserving natural respiratory mechanics, in contrast to traditional intubation that necessitates sedation and interrupts spontaneous breathing. Consequently, the incidence of ventilator-associated lung injury notably decreased, heralding a paradigm shift in respiratory management.

The implications extend beyond pulmonary benefits; the protocol demonstrated a measurable decline in secondary complications such as bronchopulmonary dysplasia and intraventricular hemorrhage. These conditions, often correlated with prolonged ventilator support and oxygen supplementation, profoundly impact long-term neurodevelopmental outcomes. By preserving lung integrity and minimizing invasive support, LISA presents a pathway toward improved survival and developmental trajectories in moderate preterm neonates.

Furthermore, the protocol streamlined the respiratory support escalation framework, facilitating earlier intervention with non-invasive ventilation strategies combined with surfactant therapy. This recalibrated approach empowers clinicians to intervene promptly while maintaining physiological stability, a balance challenging to achieve with traditional invasive techniques. The study’s robust design and substantial sample size lend confidence to the generalizability of these findings across diverse neonatal care settings.

Notably, the LISA protocol also influences nursing workflows and resource allocation. By reducing the necessity for sedation and mechanical ventilation maintenance, the protocol potentially alleviates intensive care burdens and optimizes staffing demands. This operational efficiency translates to tangible benefits for healthcare systems, particularly in resource-constrained environments where neonatal intensive care units grapple with capacity challenges.

Methodologically, the study embraced a comprehensive respiratory care framework encompassing precise timing of surfactant administration, criterion-based patient selection, and meticulous monitoring of respiratory parameters. The integration of continuous positive airway pressure (CPAP) with concurrent surfactant instillation under direct laryngoscopy minimized procedural stress and optimized surfactant uptake. Such technical finesse differentiates LISA from prior translational attempts at less invasive surfactant delivery.

Additionally, the success of the LISA protocol hinges on multidisciplinary collaboration among neonatologists, respiratory therapists, and nursing staff. Training and adherence to standardized operating procedures emerged as pivotal factors in achieving consistent outcomes. As the neonatal community assimilates these protocols, ongoing education and skill reinforcement will be indispensable to sustain procedural efficacy and safety.

The research also contributes to evolving debates surrounding the ideal gestational window for LISA utility. By focusing on infants within the 30 to 34 week range, the findings bridge knowledge gaps between extremely preterm infants who often require invasive ventilation and term newborns with transient respiratory challenges. This intermediate cohort represents a strategic target to maximize benefit while minimizing intervention-related harm.

With the global incidence of preterm birth remaining substantial, innovations like the LISA protocol address urgent public health priorities. By enhancing respiratory care during a critical developmental stage, the approach promises to diminish neonatal mortality rates and improve quality of life for survivors plagued by chronic conditions. Policymakers and healthcare administrators may increasingly advocate for protocol adoption and associated training initiatives.

Future research directions inspired by these findings include exploring adjunctive therapies compatible with LISA, refining surfactant formulation and dosing strategies, and integrating respiratory support technologies tailored for spontaneous breathing neonates. Longitudinal studies tracking neurodevelopmental and respiratory health outcomes will further elucidate the protocol’s enduring impact.

As neonatal intensive care advances toward precision and minimally invasive interventions, the LISA-based respiratory care protocol represents a landmark milestone. Its implementation commands a reevaluation of existing treatment algorithms and heralds a new era of safeguarding the fragile lungs of preterm infants through gentler, evidence-based methodologies.

In essence, the research by Ariyapadi et al. epitomizes a transformative leap in neonatology. Through meticulous clinical investigation and thoughtful procedural innovation, it charts a future where less invasive surfactant administration becomes the standard of care, optimizing respiratory resilience and fostering healthier beginnings for myriad infants worldwide.

Subject of Research: Respiratory care protocols and less invasive surfactant administration in preterm infants born at 30–34 weeks’ gestation.

Article Title: Effects of a respiratory care protocol incorporating less invasive surfactant administration in infants born at 30–34 weeks’ gestation.

Article References:
Ariyapadi, S., Bautista, L., David, L. et al. Effects of a respiratory care protocol incorporating less invasive surfactant administration in infants born at 30–34 weeks’ gestation. J Perinatol (2026). https://doi.org/10.1038/s41372-026-02682-1

Image Credits: AI Generated

DOI: 13 April 2026

Bronchopulmonary dysplasia remains a formidable challenge in neonatal medicine, particularly affecting infants born before 28 weeks gestational age or weighing less than 1000 grams. The pathophysiology of BPD is complex, involving inflammatory injury, ventilator-induced trauma, and surfactant deficiency. Surfactant replacement therapy revolutionized care decades ago by dramatically improving lung compliance and oxygenation. However, its singular use has plateaued in efficacy with respect to preventing chronic lung injury. Therefore, adjunctive therapies that modulate the inflammatory cascade are critically needed.

Budesonide’s anti-inflammatory properties have long been recognized in pediatric pulmonology, especially in asthma management. Its application to neonates, however, is relatively nascent and requires meticulous examination due to potential systemic side effects and the delicate balance of immune regulation in the developing lung. Administering budesonide directly to the lungs via the trachea coupled with surfactant aims to maximize pulmonary bioavailability while minimizing systemic exposure, thus potentially attenuating harmful inflammatory responses without jeopardizing overall neonatal development.

The mechanism by which this combination may prevent BPD lies in its targeted modulation of pulmonary immunity alongside mechanical facilitation provided by surfactant. Surfactant not only reduces alveolar surface tension but also serves as an effective vehicle for budesonide delivery, ensuring uniform distribution throughout the distal airways. This synergistic approach potentially intercepts the inflammatory cascade at multiple junctures, reducing cytokine-mediated epithelial damage and promoting alveolar maturation.

Clinicians face considerable challenges in treating extremely preterm infants, whose lungs are structurally and functionally immature. The decision to implement new protocols involving pharmacological agents such as corticosteroids must balance mitigation of lung injury against risks like neurodevelopmental impairment, growth retardation, and infection susceptibility. Hence, rigorous clinical trials evaluating safety, optimal dosing, timing, and long-term outcomes are paramount before widespread adoption.

The study conducted by Lima and Leeman introduces valuable data by evaluating long-term survival free from BPD, a clinically significant composite outcome that extends beyond mere survival or short-term respiratory improvement. Statistical analyses focusing on this combined endpoint provide a refined lens through which the efficacy of intratracheal budesonide with surfactant can be assessed. Early indications suggest an encouraging trend towards improved neonatal outcomes, heralding potential paradigm shifts in neonatal respiratory support.

Moreover, the methodology employed in the study underscores the importance of precision medicine in neonatal care. By selecting extremely preterm infants — those at highest risk — and administering the intervention shortly after birth during the critical window of lung vulnerability, researchers maximized the therapeutic window. This approach contrasts with prior steroid therapies administered systemically or later in the disease course, which often yielded equivocal or adverse results.

The implications of these findings, if validated in larger multi-centered trials, are profound. Increased survival free of BPD would translate into reduced healthcare burdens, diminished need for prolonged mechanical ventilation, decreased hospitalization costs, and improved quality of life for these infants and their families. Furthermore, preventing BPD mitigates the risk of subsequent respiratory morbidities including asthma, pulmonary hypertension, and impaired exercise tolerance during childhood and adulthood.

From a biochemical perspective, the integration of budesonide with surfactant embodies a novel drug delivery paradigm. Budesonide, typically nebulized or inhaled in older patients, is superseded by direct alveolar administration in neonates, facilitated by surfactant’s biophysical properties. This technique ensures rapid lung targeting and minimizes systemic circulation, potentially lowering side effect profiles associated with systemic steroids such as adrenal suppression and neurotoxicity.

Additional technical considerations discussed include the timing of administration relative to birth and respiratory support strategies. Administering the combination intratracheally during initial surfactant replacement allows immediate engagement with alveolar targets before extensive mechanical ventilation, which itself contributes to lung injury. This insight beckons refined protocols in delivery room stabilization and early neonatal intensive care interventions.

Despite promising data, caution prevails regarding heterogeneity in patient responses and variability in surfactant formulations. Not all formulations possess identical physicochemical characteristics to optimally carry budesonide, and neonatal lung anatomy varies considerably among subgroups. Future research must address these nuances and investigate pharmacokinetics, pharmacodynamics, and potential biomarkers predictive of responsiveness.

Ethical dimensions also arise in neonatal research, given the vulnerability of the population and the need for parental informed consent under stressful conditions. Transparency in communicating potential benefits and risks, robust oversight by ethics committees, and adherence to stringent safety monitoring protocols remain vital. Ensuring equity in access to these potentially life-saving innovations across diverse healthcare settings is an additional imperative.

Besides direct clinical outcomes, the study also provokes reflection on broader neonatal care paradigms. The successful use of intratracheal budesonide could redefine corticosteroid therapy standards and inspire the exploration of other therapeutic agents co-delivered with surfactant. Such drug-surfactant mixtures could revolutionize pulmonary pharmacotherapy in neonates, enhancing efficacy and safety profiles of multiple medications beyond steroids.

The research conducted by Lima and Leeman thus occupies a pivotal role at the intersection of neonatology, pharmacology, and bioengineering. As the neonatal community eagerly awaits larger scale validation, this preliminary evidence offers cautious optimism. It underscores the necessity of interdisciplinary collaboration, integrating clinical insight, molecular biology, and advanced drug delivery technology to surmount one of neonatology’s greatest challenges.

Ultimately, the quest to increase survival without BPD in extremely preterm infants encapsulates a larger narrative of hope, innovation, and relentless pursuit of better outcomes. A future where tiny infants breathe easier, grow stronger, and thrive outside hospital walls is being forged through such pioneering efforts. The potential transformation heralded by intratracheal budesonide mixed with surfactant may well echo across neonatal intensive care units globally, ushering a new epoch in perinatal medicine.

This emerging therapeutic strategy shines a light on the untapped potential within existing pharmacological agents, repurposed and optimized for one of medicine’s most fragile patient populations. It exemplifies the power of precision, integration, and innovation, promising a brighter respiratory future for the tiniest among us.

Subject of Research: Efficacy of intratracheal budesonide mixed with surfactant in improving survival rates without bronchopulmonary dysplasia among extremely preterm infants.

Article Title: Does intratracheal budesonide mixed with surfactant increase survival without bronchopulmonary dysplasia in extremely preterm infants?

Article References:
Lima, G.P., Leeman, K.T. Does intratracheal budesonide mixed with surfactant increase survival without bronchopulmonary dysplasia in extremely preterm infants?. J Perinatol (2025). https://doi.org/10.1038/s41372-025-02391-1

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41372-025-02391-1

Preterm birth, defined as delivery before 37 weeks of gestation, complicates approximately 10% of births in the United States, equating to about 400,000 affected infants annually. This early arrival into the world disrupts normal pulmonary development, often resulting in compromised lung architecture that may predispose survivors to chronic respiratory difficulties. Among these are increased risks for wheezing, asthma, and recurrent hospitalizations due to respiratory illnesses, conditions that may persist well into adulthood and severely diminish quality of life. Existing therapies focus primarily on stabilizing respiratory distress immediately following birth, yet the optimal duration of such interventions—particularly CPAP—remains a contentious matter in neonatology.

CPAP, a noninvasive respiratory support technique that maintains positive airway pressure through nasal prongs or masks, has become standard practice for managing respiratory distress in neonates. While early initiation of CPAP is universally accepted, clinicians typically discontinue its use once overt breathing difficulties resolve. The OHSU research team sought to interrogate whether prolonging CPAP therapy beyond this point could foster improved lung maturation, hypothesizing that mechanical support aids alveolar development and enhances gas exchange capabilities in immature lungs.

Conducting a meticulously designed randomized controlled trial involving 100 stable preterm infants, the scientists extended the CPAP treatment by two additional weeks beyond standard care intervals. By doing so, they observed remarkable enhancements in several key pulmonary metrics. At a six-month follow-up post-discharge, infants who received extended CPAP exhibited significantly greater lung volumes, an established biomarker of improved lung growth and functional capacity. Moreover, these infants demonstrated superior oxygen and carbon dioxide diffusion efficiency, underscoring improved alveolar-capillary membrane integrity and pulmonary microstructure.

The study further revealed that infants treated with prolonged CPAP experienced fewer wheezing episodes during their first year, suggesting a durable protective effect against airway hyperreactivity and inflammation that commonly affect this vulnerable population. These findings imply that a relatively simple alteration in therapeutic duration can impart substantial benefits that extend well beyond the immediate neonatal period, potentially mitigating the risk of chronic respiratory disease in later life.

Importantly, the therapy evaluated is both accessible and readily implementable across NICUs globally. CPAP devices are standard equipment, requiring no novel pharmacological agents or invasive procedures, thereby offering a low-cost, scalable intervention. The OHSU Doernbecher Children’s Hospital has already adopted this extended CPAP protocol, reporting ongoing positive outcomes in their patient cohort. Several other NICUs nationwide are currently revisiting their CPAP management strategies in light of these compelling results.

Despite these promising revelations, the researchers caution that further studies are essential to delineate the optimal CPAP duration for varied strata within the preterm infant population. Infants with very low birth weights or additional co-morbidities may require tailored approaches, and longitudinal data are crucial to ascertain sustained respiratory benefits or potential unforeseen consequences. To that end, the investigative team plans to monitor the original trial cohort through age 10, employing annual lung function assessments to parse the long-term impact of extended CPAP therapy on pulmonary health trajectories.

Mechanistically, the findings align with emerging insights into lung developmental biology. The preterm lung is characterized by arrested alveolarization and reduced surface area for gas exchange. By providing a sustained distending pressure, CPAP may prevent atelectasis, maintain airway patency, and promote optimal mechanical stretch-induced signaling pathways pivotal for alveolar septation and vascularization. This mechanotransduction is vital for establishing robust, functional lung architecture capable of efficient respiration.

From a clinical standpoint, this research reframes our understanding of neonatal respiratory management, emphasizing that timing and duration of interventions are as critical as their presence. Extending CPAP therapy represents a nonpharmacological strategy that is safe, efficient, and capable of modifying the natural history of lung disease in preterm infants. Such interventions may ultimately reduce the burden of chronic respiratory ailments, health care costs, and improve life quality for patients born prematurely.

Dr. Cindy McEvoy, the principal investigator and a professor of pediatrics at OHSU’s School of Medicine, highlights the transformative potential of this work. She states, “Adjusting the duration of CPAP application offers a safe and actionable method to influence lung development positively. Our aim is to ensure these infants have the best possible respiratory outcomes throughout their lives.” Her statement underscores a shift towards proactive optimization of neonatal treatments beyond immediate survival, targeting lifelong health outcomes.

Dr. Dmitry Dukhovny, medical director of the NICU at OHSU Doernbecher Children’s Hospital, further emphasizes the accessibility of this intervention, noting its ubiquity in NICUs and ease of implementation. “By simply modifying how long we administer CPAP, we can profoundly impact lung function development. This study exemplifies how small changes in clinical practice can have outsized benefits,” he notes.

In summation, the OHSU study substantiates that prolonged CPAP administration in stable preterm infants results in enhanced lung growth, improved pulmonary gas exchange, and reduced respiratory morbidity during infancy. It heralds a new era in neonatal respiratory care, where treatment duration is intelligently tailored to optimize developmental outcomes. The broader neonatal community is poised to embrace these findings, with ongoing trials and longitudinal investigations anticipated to solidify extended CPAP as a new standard of care.

Subject of Research: Extended continuous positive airway pressure therapy and its effects on lung growth and function in preterm infants.

Article Title: Extended Continuous Positive Airway Pressure in Preterm Infants Increases Lung Growth at 6 Months: A Randomized Controlled Trial

Web References:
https://www.atsjournals.org/doi/10.1164/rccm.202411-2169OC
https://www.ohsu.edu/doernbecher/neonatal-intensive-care-unit-nicu

References:

• McEvoy, C. et al. (2024). Extended Continuous Positive Airway Pressure in Preterm Infants Increases Lung Growth at 6 Months: A Randomized Controlled Trial. American Journal of Respiratory and Critical Care Medicine. DOI: 10.1164/rccm.202411-2169OC

Keywords: Infants, Lungs, Respiration, Disease intervention, Clinical research